Condition

Myeloproliferative Neoplasm clinical trials and research

• 37Clinical trials
• 12NIH research projects
• 10Countries

Newest Myeloproliferative Neoplasm clinical trials

All recruiting trials (37)

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Using NETosis blood markers to predict clot risk in JAK2-positive myeloproliferative neoplasms

  This study will try to see if blood markers of NETosis can predict clotting risk in people with JAK2V617F-positive myeloproliferative neoplasms who are at high risk for thrombosis.

  Recruiting University Hospital, Bordeaux · Angers and 14 other locations · NCT07119970

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant

  This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06815003

• Study of characteristics and complications in young patients with myeloproliferative neoplasia

  This study is trying to gather information about young people under 30 with myeloproliferative neoplasia to better understand their health and complications.

  Recruiting University Hospital, Brest · Brest · NCT06715267

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

• Understanding the risks of thrombosis in CALR-mutated MPN patients

  This study is trying to understand why people with CALR mutations in myeloproliferative neoplasms have a different risk of blood clots compared to those with JAK2 mutations by looking at certain blood markers.

  Recruiting at 2 sites Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT06480591

• Comparing two conditioning regimens for haploidentical stem cell transplantation

  This study is testing two different treatment plans for patients getting stem cell transplants from partially matched donors to see which one works better in preventing complications like graft failure and relapse.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06477549

• Investigating how monocytes affect blood cell growth in myeloproliferative neoplasia

  This study is trying to see how certain immune cells called monocytes affect the growth of blood cells in people with myeloproliferative neoplasia.

  Recruiting University Hospital, Brest · Brest · NCT06462664

• Brain imaging in young patients with acute leukemia

  This study is testing how chemotherapy affects the brains of children and young adults with acute leukemia to see if it causes any thinking problems and to find ways to help them.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06421155

• Characterizing Monocytes in Blood Disorders

  This study is trying to learn more about the role of certain blood cells called monocytes in patients with specific blood disorders to see how they might affect the disease and treatment options.

  Recruiting University Hospital, Angers · Angers, Maine et Loire and 2 other locations · NCT06361641

• CIML NK cell therapy to prevent relapse after stem cell transplant

  This study is testing if a new type of immune cell therapy can help prevent relapse in people with certain blood cancers after they receive a stem cell transplant.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06138587

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Vaccination to prevent CMV infection in stem cell transplant patients

  This study is testing a new vaccine to see if it can help prevent CMV infections in patients receiving stem cell transplants from related donors.

  Recruiting at 3 sites Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT06059391

• Examining the role of epigenetic age in myeloproliferative neoplasms

  This study is trying to see if the biological age of DNA can help predict how well people with myeloproliferative neoplasms will do and if they might face complications like blood clots.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT06022328

• Using cord blood transplant and chemotherapy to treat high-risk blood cancers

  This study is testing if combining umbilical cord blood transplants with certain chemotherapy treatments can help people with high-risk blood cancers do better and have fewer side effects.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06013423

• Registry of Asian patients with myeloproliferative neoplasms

  This study is collecting information from Asian patients with myeloproliferative neoplasms to learn more about their condition and how different treatments work for them.

  Recruiting The University of Hong Kong · Hong Kong · NCT05882773

• Understanding how interferon works for treating myeloproliferative neoplasms

  This study is trying to see how a treatment called pegylated interferon works for people with certain blood cancers to understand why some patients respond better than others.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Villejuif, Île-de-France Region · NCT05850273

• Analyzing the Clonality Profile in Myeloproliferative Neoplasms and Thrombotic Risks

  This study is trying to see if measuring certain genetic markers in blood cells can help predict the risk of blood clots in people with Myeloproliferative Neoplasms.

  Recruiting at 10 sites University Hospital, Bordeaux · Angers and 10 other locations · NCT05839717

• Stem cell transplant using a specific preparative regimen for blood cancers

  This study is testing a new way to prepare for a stem cell transplant using a special combination of medications and radiation to see if it helps people with acute leukemia who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05805605

• Impact of Leukemia and Lymphoma Society services on blood cancer patients

  This study is testing how the services provided by the Leukemia and Lymphoma Society can help people with blood cancers feel better and manage their care over six months.

  Recruiting University of Miami · Miami, Florida and 2 other locations · NCT05745285

• Testing Optical Genome Mapping in Ph-Negative Myeloproliferative Neoplasms

  This study tests whether Optical Genome Mapping can better detect chromosomal changes in adults with Ph-negative myeloproliferative neoplasms who need bone marrow cytogenetics.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT05714592

• Treatment of FGFR1-rearranged neoplasms with Olverembatinib

  This study is testing if a new drug called Olverembatinib can help people with rare blood cancers caused by FGFR1 changes get better and possibly prepare them for a stem cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT05521204

• Predicting response to hydroxyurea or pegylated interferon in polycythemia vera, essential thrombocythemia, and pre-myelofibrosis

  We will test whether genetic mutations and cytokine levels at diagnosis can predict who will respond to hydroxyurea or pegylated interferon in people with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis.

  Recruiting at 6 sites University Hospital, Angers · Angers and 5 other locations · NCT05440838

• Finding the best dose of N-Acetylcysteine for patients with blood disorders

  This study is testing the best dose of N-Acetylcysteine to see if it can help people with certain blood disorders feel better while they continue their usual treatments.

  Recruiting Phase 1/2 University of California, Irvine · Irvine, California and 1 other locations · NCT05123365

• Combining venetoclax and azacitidine for advanced myeloproliferative neoplasms

  This study is testing if combining two drugs, venetoclax and azacitidine, can help people with advanced blood cancers feel better and manage their disease.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT05074355

• Evaluating CALR Allele Burden in Myeloproliferative Neoplasms

  This study is trying to see if tracking a specific genetic change in the blood can help doctors understand how myeloproliferative neoplasms progress in patients over time.

  Recruiting at 10 sites University Hospital, Angers · Angers and 9 other locations · NCT04942080

• Improving cognitive function in older adults after stem cell transplant

  This study is testing if a special exercise program can help older adults who had a stem cell transplant think better and improve their brain health.

  Recruiting University of Nebraska · Omaha, Nebraska · NCT04898790

• Combining CPX-351 and ivosidenib for treating IDH1 mutated acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a combination of two treatments, CPX-351 and ivosidenib, to see if they can help people with acute myeloid leukemia or high-risk myelodysplastic syndrome who have an IDH1 mutation.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04493164

• Combining decitabine with ruxolitinib, fedratinib, or pacritinib for treating advanced myeloproliferative neoplasms

  This study is testing if combining decitabine with other medications can help patients with advanced blood cancers get ready for a stem cell transplant.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT04282187

• CIML NK cell infusion for relapsed myeloid disease after stem cell transplant

  This trial tests whether giving cytokine‑induced memory‑like (CIML) natural killer cells together with low‑dose IL‑2 can help adults (≥18) and teens (≥12) whose AML, MDS, MPN, or JMML has returned after a stem cell transplant.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04024761

• Strategies to reduce graft versus host disease in blood stem cell transplant patients with acute leukemia or MDS

  This study is testing two different treatment plans to see which one better helps prevent graft versus host disease in patients with acute leukemia or myelodysplastic syndrome after they receive a blood stem cell transplant.

  Recruiting at 3 sites Phase 2 Fred Hutchinson Cancer Center · Tampa, Florida and 2 other locations · NCT03970096

• Using edetate calcium disodium or succimer to treat acute myeloid leukemia or myelodysplastic syndrome during chemotherapy

  This study is testing whether two drugs, edetate calcium disodium and succimer, can safely help people with acute myeloid leukemia or myelodysplastic syndrome feel better during chemotherapy.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT03630991

• Using dexrazoxane to protect the heart during chemotherapy for blood cancers

  This study is testing if a drug called dexrazoxane can help protect the hearts of people with blood cancers from damage caused by chemotherapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03589729

• Combining Ivosidenib and Venetoclax with or without Azacitidine for treating IDH1 mutated blood cancers

  This study is testing a combination of two drugs, ivosidenib and venetoclax, with or without azacitidine, to see if it helps people with certain types of blood cancers that have an IDH1 mutation.

  Recruiting at 4 sites Phase 1/2 M.D. Anderson Cancer Center · Boston, Massachusetts and 3 other locations · NCT03471260

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Gathering health information for younger cancer patients

  This study is gathering health information from younger cancer patients to help improve treatments and support future research.

  Recruiting at 253 sites Children's Oncology Group · Birmingham, Alabama and 278 other locations · NCT02402244

NIH-funded research (12)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Complement and clotting in JAK2V617F myeloproliferative neoplasms

  A short, patient-friendly study will look at how a specific mutation in blood cells may trigger the body’s complement system to cause clots in people with myeloproliferative neoplasms.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11437026

• Endothelial contribution to blood-clotting in myeloproliferative neoplasms

  This project explores how the lining of blood vessels may drive dangerous clots in people with myeloproliferative neoplasms (MPNs).

  NIH research University of Minnesota · Minneapolis, United States · NIH-11392884

• Hypoxia-inducible factors and neutrophil diversity in blood clotting in myeloproliferative neoplasms

  A physician-scientist is training over five years to uncover how low-oxygen signals and diverse neutrophils drive dangerous clots in people with myeloproliferative neoplasms, with the goal of finding new treatment targets.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11380793

• Inherited genetic risks shaping myeloid cancer initiation

  A research project at Boston Children’s Hospital is exploring how inherited genetic differences may push blood stem cells toward the start of myeloproliferative neoplasms, with potential implications for earlier detection and prevention.

  NIH research Boston Children's Hospital · Boston, United States · NIH-11364935

• Understanding why some myeloproliferative neoplasm patients resist interferon therapy

  Researchers are studying why interferon-alpha works for some blood cancer patients but not others, by looking closely at stem cells from CALR-mutated myeloproliferative neoplasms.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11357543

• Genetic and epigenetic factors shaping response in advanced myeloproliferative neoplasms

  This grant looks at how genetic and epigenetic differences influence how patients with advanced myeloproliferative neoplasms respond to therapies.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11352898

• Understanding why some patients with blood cancers don't respond to interferon-alpha treatment

  This study is looking at how certain blood cancer stem cells with CALR mutations react to a treatment called interferon-alpha, to help understand why some patients improve in their blood counts but not in tumor size, which could lead to better treatments for people with blood cancers.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11180710

• Understanding inherited risks for blood cancers called myeloproliferative neoplasms

  This work explores how inherited genetic differences can make some people more likely to develop certain blood cancers, called myeloproliferative neoplasms.

  NIH research Boston Children's Hospital · Boston, United States · NIH-11114017

• Understanding why some patients with blood cancers don't respond to interferon-alpha treatment

  This study is looking at how a specific type of blood cancer stem cell, especially those with CALR mutations, reacts to a treatment called interferon-alpha, to help understand why some patients benefit from the therapy even if their tumors don't shrink, with the goal of finding better treatment options for people with

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11087672

• Understanding blood clotting mechanisms in certain blood cancers

  This study is looking into how blood clots form in people with myeloproliferative neoplasms (a type of blood cancer) to find new ways to help prevent serious complications, and it’s designed for patients who want to learn more about their condition and potential treatments.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-10895397

• Understanding how blood vessel cells contribute to blood clots in certain blood cancers

  This study is looking at how certain cells in your blood vessels might contribute to blood clots in people with myeloproliferative neoplasms (MPNs), especially those with a specific mutation, and it aims to understand how current medications can help, with the possibility of you providing blood samples to assist in thi

  NIH research University of Minnesota · Minneapolis, United States · NIH-10895325

• Understanding inherited genetic factors that lead to blood cancers.

  This study is looking at how inherited genes might play a role in the development of blood cancers called myeloproliferative neoplasms, using mice to understand how these genes affect blood stem cells, which could help patients learn more about their own genetic risks and ways to prevent these conditions.

  NIH research Boston Children's Hospital · Boston, United States · NIH-10867306

Related topics

Quick answers

How many Myeloproliferative Neoplasm clinical trials are recruiting right now?

37, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 10 countries. The most sites are in United States (22 trials), France (10 trials), Russia (2 trials), Canada (2 trials), Puerto Rico (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 12, Phase 1: 4, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →